IMARA  logo
IMARA IMRA
report update icon

Quarterly report 2026-Q2
added 08-05-2026

IMARA Balance Sheet 2025-2011 | IMRA

Brief overview of IMARA 's assets and capital

The review uses the five latest available annual reports between 2021 and 2025.

Assets reached $476.2 million, compared with $93.6 million at the beginning. Growth of +408.5% and CAGR near 50.2% show active expansion.

Growth in the asset base was not matched by liabilities: +408.5% versus +117.5%. The balance sheet moved in a more conservative direction.

Internal capital represents 96.5% of the balance sheet, previously 91.9%. This is a strong capital position.

Cash equals 20.8% of the balance sheet, compared with 51.6% five periods ago. This is the readily available cushion.

Retained earnings are negative at -$347.2 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.

What the balance sheet shows

IMARA retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.

Annual Balance Sheet IMARA

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - -74.9 M -47.7 M -47.7 M -4.94 M -7.38 M - - - - - - -

Long Term Debt

- - - 321 K 406 K - - - - - - - - - -

Long Term Debt Current

399 K - 335 K 323 K 246 K - - - - - - - - - -

Total Non Current Liabilities

- - - - - 160 K 184 K 32.2 M - - - - - - -

Total Current Liabilities

16.6 M 15.9 M 25.9 M 9.72 M 7.21 M 6.25 M - - - - - - - - -

Total Liabilities

16.6 M 15.9 M 26 M 10.4 M 7.62 M 6.41 M 4.38 M 34 M - - - - - - -

Retained Earnings

-347 M -243 M -154 M -82.9 M -147 M -96.1 M -54.8 M -31.3 M - - - - - - -

Total Assets

476 M 326 M 272 M 83.3 M 93.6 M 90.8 M 33.3 M 7.7 M - - - - - - -

Cash and Cash Equivalents

98.9 M 124 M 100 M 75.5 M 48.3 M 47.7 M 5.02 M - - - - - - - -

Book Value

460 M 310 M 246 M 72.9 M 86 M 84.4 M 28.9 M -26.3 M - - - - - - -

Total Shareholders Equity

460 M 310 M 246 M -76.8 M 86 M 84.4 M -48.8 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet IMARA

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

913 K - 103 K 204 K 302 K - - - - - 81 K 162 K 242 K - - - 1.97 M 406 K 466 K 528 K 590 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

15.1 M 11.5 M 14.8 M 15.4 M 14.3 M 15.9 M 17 M 22.1 M 25.1 M 26 M 12.3 M 9.51 M 11.4 M 10.4 M 1.82 M - 9.19 M 7.62 M 7.65 M 7.5 M 6.09 M 6.41 M 6.41 M 6.41 M 6.41 M 4.38 M 4.38 M 4.38 M 4.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-403 M -371 M -317 M -297 M -272 M -243 M -220 M -197 M -177 M -154 M -135 M -114 M -97.6 M -82.9 M -178 M - -162 M -147 M -133 M -120 M -106 M -96.1 M -96.1 M -96.1 M -96.1 M -54.8 M -54.8 M -54.8 M -54.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

910 M 465 M 491 M 504 M 303 M 326 M 305 M 327 M 343 M 272 M 274 M 289 M 303 M 83.3 M 59.1 M - 81.6 M 93.6 M 107 M 72.5 M 81.7 M 90.8 M 90.8 M 90.8 M 90.8 M 33.3 M 33.3 M 33.3 M 33.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

136 M 132 M 102 M 119 M 102 M 124 M 101 M 96.9 M 149 M 100 M 73.8 M 126 M 292 M 75.5 M 86.2 M 92.5 M 99.9 M 48.3 M 75.3 M 48 M 53.4 M 47.7 M 47.7 M 47.7 M 47.7 M 4.94 M 4.94 M 4.94 M 4.94 M 7.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

895 M 453 M 476 M 488 M 288 M 310 M 288 M 305 M 318 M 246 M 262 M 279 M 291 M 72.9 M 57.3 M - 72.4 M 86 M 99.4 M 65 M 75.6 M 84.4 M 84.4 M 84.4 M 84.4 M 28.9 M 28.9 M 28.9 M 28.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

895 M 453 M 476 M 488 M 288 M 310 M 288 M 305 M 318 M 246 M 262 M 279 M 291 M -76.8 M -68.1 M -58.7 M -50.6 M 86 M 99.4 M 65 M 75.6 M 84.4 M 84.4 M 84.4 M 84.4 M -48.8 M -48.8 M -48.8 M -48.8 M -26.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of IMARA , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.6 5.56 % $ 6.41 B israelIsrael
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 64.67 0.11 % $ 12.4 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.85 0.12 % $ 319 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.78 1.13 % $ 3.03 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 34.07 0.17 % $ 382 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 5.6 2.06 % $ 3.74 M usaUSA
Codexis Codexis
CDXS
$ 1.59 0.3 % $ 139 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.1 1.25 % $ 303 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 199.02 0.31 % $ 9.9 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.28 0.1 % $ 1.62 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aytu BioScience Aytu BioScience
AYTU
$ 2.25 0.45 % $ 14.1 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada